Skip to main navigation Skip to search Skip to main content

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

  • AJ (Diane) van der Biessen
  • , JA Gietema
  • , Maja de Jonge
  • , IME Desar
  • , M W den Hollander
  • , M Dudley
  • , M Dunbar
  • , R Hetman
  • , C Serpenti
  • , H (Hong) Xiong
  • , RK Mittapalli
  • , KM Timms
  • , P Ansell
  • , CK Ratajczak
  • , SP Shepherd
  • , CML van Herpen
  • External organisation

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
18 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)828-835
Number of pages8
JournalInvestigational New Drugs
Volume36
Issue number5
DOIs
Publication statusPublished - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research programs

  • EMC MM-03-86-08

Cite this